Nanomedicine is a profitable business
The volume of the nanomedicine market in 2019 may reach 177.6 billion US dollars
Weekly Pharmacy www.apteka.ua based on PR Newswire materials:
Nanomedicine Market is Expected to Reach USD 177.60 Billion Globally in 2019: Transparency Market ResearchAccording to the report "Nanomedicine Market (Neurology, Cardiovascular, Anti-inflammatory, Anti-infectious, and Oncology Applications) – Global Industry Analysis, Size, Share,Growth, Trends and Forecast, 2013-2019", published in Transparency Market Research, the nanomedicine market in 2012 was estimated at 78.54 billion dollars.
It is expected to reach $177.6 billion in 2019. The level of its annual growth in the period from 2013 to 2019 will be equal to an average of 12.3% in monetary terms.
The global nanomedicine market can be divided into parts. In the context of therapeutic areas, there are 6 segments of it: drugs used in neurology, cardiovascular, anti-inflammatory drugs, drugs used in oncology and drugs for the treatment of other diseases. By geographical indicator, the nanomedicine market is divided into the following segments: North America, Europe, Asia-Pacific region, and other regions.
The key players in the global market are: «GE Healthcare», «Merck& Co. Inc.», «Abbott Laboratories», «Pfizer Inc.», «Nanosphere Inc.», «Mallinckrodt PLC», «Teva Pharmaceutical Industries Ltd», «Sigma-Tau Pharmaceuticals Inc.», «Celgene Corporation», «Novavax Inc», «Life Technologies», «MagArray Inc.», «Gilead Sciences Inc.».
Among the growth factors of the nanomedicine market are: the emergence of new products and technologies in this field; increased funding from the government and private organizations aimed at intensifying research activities, which, in turn, contributes to the speedy commercialization of new products; an increase in the proportion of the elderly population in the world; the presence of unmet medical needs; an increase in the number of cases of chronic diseases in the world.
In 2012, among the segments of the nanomedicine market in the context of therapeutic groups with a share of about 38% in monetary terms, drugs used in oncology dominated, due to the presence of a large number of commercialized products in this segment. In the future, it is expected that the most significant driver of the growth of this market segment will be drugs that can pass through the blood-brain barrier and act directly on a tumor in the brain.
However, the fastest growing segment of the market is considered to be drugs for the treatment of cardiovascular diseases. According to forecasts, factors such as the high prevalence of diseases of the cardiovascular system, as well as the growing demand for nanotechnology, will provide such medicines and devices with high sales growth rates.
North America took the 1st place in the nanomedicine market in 2012. It is expected that it will be able to maintain its position until 2019. Nevertheless, the Asia-Pacific market is estimated to grow quite rapidly (by an average of 14.6% annually from 2013 to 2019). In turn, the European nanomedicine market is also expected to show rapid growth rates due to the constantly improving regulatory framework and the availability of a wide range of products.
Portal "Eternal youth" http://vechnayamolodost.ru13.01.2014